Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)

change from baseline (previous study) in the mean FSDS-R question 13 score to week 12 of the current study

This study is to acess the persistence of benefit following the withdrawal of testosterone gel 1% (LibiGel)in the treatment of Hypoactive Sexual Desire Disorder (HSDD) in healthy, surgically menopausal women.

Time frame: 12 weeks

change from baseline (previous study) in the total number of days with at least one satisfying sexual event at weeks 4 and 8 of the current study

This study is to assess the persistence of benefit following the withdrawal of testosterone gel (LibiGel)in the treatment of Hypoactive Sexual Desire Disorder (HSDD) in healthy, surgically menopausal women.

Time frame: 12 weeks